Expert Interview
Analyzing the Chances of Approval and Market Potential for Bavarian Nordic's (BAVA) CV-301 in Respiratory Syncytial Virus (RSV) Ahead of Phase II Initiation in H2 2016
Ticker(s): BAVAAn expert with significant experience treating patients with respiratory syncytial virus, who is familiar with the data behind CV-301. He or she will be familiar with other drugs in the space, as well as the regulatory process faced by BAVA.
Can you describe your experience treating patients with RSV? What drugs are currently used? What other ways is RSV treated?
Added By: pjloriaCan you discuss the safety and efficacy of current treatment options for RSV?
Added By: pjloriaCan you discuss any available data on CV-301?
Added By: pjloriaWhat are your expectations for the data from the clinical trial of the MVA-BN RSV program that is expected in the first half of 2016? What are important things to look for in this data release?
Added By: pjloriaWhat are your expectations for the Phase II trial that is scheduled to start in the second half of 2016? What are important things to look for in this trial?
Added By: pjloriaGiven the current information, how do you view the chances of approval for CV-301 in RSV?
Added By: pjloriaAssuming it receives approval, what percentage of existing RSV patients will switch to CV-301? What percentage of new patients will be put on CV-301?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
